Tag Archives: healthcare

Hoosier Foot & Ankle Joins Upperline Health

Upperline Health, leader in lower-extremity care, has partnered with Hoosier Foot & Ankle, a 9 physician and 11 clinic group serving the greater Indianapolis area. Patrick DeHeer, DPM and 8 associates will be joining the Upperline Health team through the partnership.

“Hoosier Foot & Ankle is a huge partnership for Upperline Health in Indiana,” said Michael King, DPM, Chief Medical Officer at Upperline Health. “Our rapid growth in the Indianapolis area and partnership with these top-notch foot and ankle specialists will allow Upperline Health to continue serving more patients in need across the country.”

“I have put my heart and soul into building Hoosier Foot & Ankle into something special over the past 16 years, and I am thrilled to be partnering with Upperline Health,” said DeHeer. “Upperline’s strategic plan and vision are exciting and market changing. Being part of such an innovative organization that puts patient outcomes first using data-driven care is game changing.”

In addition to Dr. DeHeer, Hoosier Foot & Ankle includes the following associate physicians: Farwa Abid-Hoffman, DPM, AACFAS; Christine Bhinder, DPM; Bryan Camp, DPM; Anthony Jagger, DPM; David Smith, DPM; Richard L. Thatcher, DPM; Tyler Vestile, DPM; and Aaron Warnock, DPM, AACFAS.

About Hoosier Foot & Ankle

As a premier podiatry clinic in the Greater Indianapolis area and Kokomo, the team at Hoosier Foot & Ankle offers comprehensive care and treatment all under one roof. The team’s practice philosophy is based upon providing superior, honest and cutting-edge professional care for each and every patient. The podiatrists are committed to offering the latest and most effective technologies and procedures available on the market. Learn More

About Upperline Health

Upperline Health provides the highest quality integrated extremity care to patients in need through a skilled and compassionate team. Upperline Health is building out a network of the top physicians and practices across the country while partnering with health plans and community providers to deliver care in a consistent and high-quality manner.

Upperline Health is one of the nation’s largest practices dedicated to lower extremity care with providers in Alabama, California, Florida, Indiana and Tennessee.

‍

Categories: News

Tags:

Salvia BioElectronics

Inkef Capital

Salvia BioElectronics receives FDA Breakthrough Device Designation for innovative neurostimulation solution

 Bioelectronics solution addresses drug-refractory chronic migraine

Eindhoven, the Netherlands, November 3, 2020 – Salvia BioElectronics B.V. (“Salvia”), a neurostimulation platform company targeting chronic migraine, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its implantable neurostimulation system to address chronic migraine.

Salvia is developing an innovative neurostimulation solution for chronic migraine based on a novel device concept with unique benefits to both patients and physicians. Migraine is the first cause of disability in under 50s, affecting one out of seven people, predominantly women[1]. People with migraine experience episodes of throbbing, pulsating pain, sometimes accompanied by nausea, vomiting, and sensitivity to light, that can last anywhere from a few hours to a few days. More than five percent of patients suffer from chronic migraine, where they experience migraines for an average of 22 days per month[2]. Migraine does not only impact wellbeing; it has an enormous impact on work, school, family and social lives.

Wim Pollet, Chief Medical Officer of Salvia BioElectronics, noted: “The FDA breakthrough device designation of our neurostimulation system reflects the recognition of the large unmet medical need of patients suffering from refractory chronic migraine, and the potential of Salvia’s bioelectronic foil technology to address this. We look forward to working closely with the FDA to expedite the review process to accelerate the development of our therapy.”

Patients with chronic migraine suffer from 15 or more headache days per month, with an average of 22 days per month, despite best medical treatment1. Only 1 in 3 of drug-refractory chronic patients are helped with the newest generation of anti-migraine drugs, leaving many patients in medical need.

While neurostimulation has been demonstrated to be effective for these patients, there are no approved devices commercially available. Salvia was founded with the mission to help these patients suffering from chronic migraine by developing thin and conforming bioelectronic foils that uniquely adapt to the anatomy of the head.

The FDA’s Breakthrough Devices Program has been established to help patients to have more timely access to medical devices that provide more effective treatment for irreversibly debilitating diseases or conditions. The designation allows Salvia to have more frequent interaction with the FDA regulatory experts when preparing its FDA submissions, followed by prioritized reviews.

 

Enquiries

For more information please contact:

Salvia BioElectronics

Daniel Schobben, Chief Operating Officer

mb.info@salvianeuro.com

 

Optimum Strategic Communications

Supriya Mathur, Elakiya Rangarajah

+44 (0) 20 3922 1906 / +44 (0) 203 922 0891

Salvia@optimumcomms.com

 

 About Salvia BioElectronics B.V.

Salvia BioElectronics is an innovative Dutch startup active in the emerging field of bioelectronics. Salvia BioElectronics was founded in 2017 by neuromodulation industry veterans with the ambition to develop a bioelectronics therapy for people suffering from chronic migraine that is as easy as taking medication yet side-effect free. Building on research around known neural targets in migraine, the startup is working to develop the right form factor for stimulation that is effective, safe, and affordable.

Migraine is the first cause of disability in under 50s, affecting one out of seven people, predominantly women. People with migraine experience episodes of throbbing, pulsating pain, sometimes accompanied by nausea, vomiting, and sensitivity to light, that can last anywhere from a few hours to a few days. More than five percent of patients experience migraines for 15+ days per month – with an average of 22 days – a condition described as chronic migraine. www.salvianeuro.com

[1]Steiner, T.J., Stovner, L.J., Vos, T. et al. Migraine is first cause of disability in under 50s: will health politicians now take notice?. J Headache Pain 19, 17 (2018). https://doi.org/10.1186/s10194-018-0846-2

[2]Richard B Lipton, Merle L Diamond, Stewart J Tepper, Expert Perspectives—Migraine Prevention for Highly Impacted Patients.

Categories: News

Tags:

Data-powered clinical development and commercialisation

Gp Bullhound

30 October 2020

Definitive Healthcare, the leading provider of data, intelligence and analytics on the healthcare market, today announced its acquisition of Monocl, the leading subscription-based provider of medical and scientific expert data and insights.

Monocl delivers deep professional profiles on millions of experts worldwide, to help companies identify and engage industry opinion leaders. Through the transaction, Definitive fortifies its product offerings for life sciences companies and expands its international presence from North America to Europe and Asia.

“Monocl has always been laser focused on delivering critical expert insights through software to provide our clients with a unique competitive and collaborative edge,” said Björn Carlsson, CEO and co-founder of Monocl. “We are thrilled to unite the power of our groundbreaking expert platform with Definitive’s comprehensive and complementary healthcare provider platform and medical claims analytics. This is truly an example of the whole being much greater than the sum of its parts.”

“The acquisition of Monocl brings together two powerful intelligence platforms to provide best-in-class data, analytics and insight that will help biotech and pharmaceutical companies accelerate clinical research and commercialisation of new drugs and therapies,” said Jason Krantz, founder and CEO of Definitive Healthcare. “Monocl shares the Definitive philosophy of providing the highest quality data through an online interface that gives clients the ability to access and analyse real-time information and intelligence.”

Joakim Dal, Partner at GP Bullhound, added: “Björn and his team have put a very powerful application in the hands of Monocl’s customers. The superior user interface and the vast data library makes this a standard for enterprise applications. During our investment period, Monocl has developed at a rapid pace. We look forward to what the combination of these two leading companies can do to support the critical work in the life sciences sector.”

GP Bullhound invested in Monocl in 2019 through GP Bullhound Fund IV, which focuses on growth stage businesses in the software, digital media, marketplaces and fintech sectors. Other investments include Revolut, Slack, Klarna, Unity, RavenPack and Believe.

Enquiries

For enquiries, please contact:

Joakim Dal, Partner

joakim.dal@gpbullhound.com

About GP Bullhound

GP Bullhound is a leading technology advisory and investment firm, providing transaction advice and capital to the world’s best entrepreneurs and founders. Founded in 1999, the firm today has offices in London, San Francisco, Stockholm, Berlin, Manchester, Paris, Hong Kong, Madrid and New York. For more information, please visit www.gpbullhound.com.

 

 

Categories: News

Tags:

Patricia Industries’ acquisition of Advanced Instruments completed

Investor

2020-10-30 19:19 GMT+01

On September 28, 2020, Patricia Industries, a part of Investor AB, announced the acquisition of US company Advanced Instruments, the leading global provider of osmolality testing instrumentation and consumables for the clinical, biopharmaceutical, and food & beverage markets.

Following approval by the competition authorities, the acquisition has now been completed.

The enterprise value amounts to USD 780m. For the 12-month period ending June 30, 2020, sales amounted to USD 72m and the adjusted EBITDA margin was approximately 45 percent. Over the past 15 years, organic sales growth has averaged approximately 10 percent, with strong profitability and cash conversion.

Patricia Industries has injected USD 619m in equity financing for 98 percent ownership of the company. The remainder of the enterprise value has been financed by external debt and equity participation by Advanced Instrument’s management and Board of Directors.

Advanced Instruments’ Board of Directors will be chaired by David Perez, former CEO of Terumo BCT and current board member of Mölnlycke, Laborie and Sarnova.

About Patricia Industries
Patricia Industries is a long-term owner that invests in companies and works to develop each company to its full potential. Patricia Industries is a part of the industrial holding company Investor AB, whose main owners are the Wallenberg foundations.

For further information:

Viveka Hirdman-Ryrberg, Head of Corporate Communication and Sustainability,
Phone +46 70 550 3500
viveka.hirdman-ryrberg@investorab.com

Magnus Dalhammar, Head of Investor Relations,
Phone +46 73 524 2130
magnus.dalhammar@investorab.com

Our press releases can be accessed at www.investorab.com

Investor, founded by the Wallenberg family in 1916, is an engaged owner of high quality global companies. We have a long-term investment perspective. Through board participation, as well as industrial experience, our network and financial strength, we work continuously to support our companies to remain or become best-in-class. Our holdings include, among others, ABB, Atlas Copco, Ericsson, Mölnlycke and SEB.

Categories: News

Tags:

RapidSOS to Deliver MedicAlert User Information to 999 Systems During Emergencies

C5 Capital

Categories: News

Tags:

Relievant Medsystems Announces $70M Financing to Accelerate U.S. Commercialization of Intracept Procedure

OCTOBER 29, 2020 – MINNEAPOLIS, MN. Relievant Medsystems, a privately-held medical device company transforming the treatment of Chronic Low Back Pain (CLBP), announced today the completion of a $70 million equity financing. The round was led by new investor Vensana Capital alongside Lightstone Ventures with participation from existing investors Endeavour Vision, New Enterprise Associates, Morgenthaler Ventures and Canaan Partners.

“This oversubscribed financing round is a great vote of confidence in our team, product and mission to change the treatment paradigm for CLBP,” said Art Taylor, President and CEO of Relievant Medsystems. “2020 will be a record year for Relievant and the commercialization of the Intracept Procedure. With the recent publication of our 5-year data showing sustained improvements in pain and function, we expect even greater adoption in 2021 as more and more physicians make Intracept a core part of their CLBP patient care pathway. We are delighted to have such strong financial support to fuel this rapid commercial growth and to make this much-needed treatment available to more patients and physicians.”

Chronic low back pain is a widespread and often severely debilitating condition estimated to affect nearly 30 million people in the U.S., with over 70 percent failing to find adequate relief with conservative care and are not candidates for surgery. Until recently, the intervertebral discs have been thought to be the primary source of pain, referred to as discogenic pain, in most patients with CLBP. Relievant’s Intracept Procedure is a minimally invasive treatment based upon ground-breaking anatomic research that demonstrated many of these patients actually suffer from vertebrogenic pain – pain originating from the vertebral endplates that is transmitted through the basivertebral nerve. The Intracept Procedure is supported by two Level I randomized controlled clinical trials and long-term data demonstrating improvements in pain and function lasting more than 5-years post-procedure. It is estimated that over five million CLBP patients in the U.S. have vertebrogenic pain and are candidates for the Intracept Procedure.

As part of the financing, Justin Klein, MD, JD, Co-Founder and Managing Partner at Vensana Capital, will join Relievant’s board of directors.

“The team at Relievant has created a category-defining medical procedure that truly has the potential to transform the treatment of CLBP,” said Justin Klein. “The Intracept procedure is a safe, patient-friendly treatment that has resonated with physician leaders in the field and has been proven to significantly reduce pain and disability, now beyond five years in well-conducted clinical trials. With the millions of patients in the U.S. suffering from chronic axial low back pain indicated for Relievant’s Intracept Procedure, we believe Intracept is an outstanding example of medical technology innovation and is one that can also positively impact our country’s ongoing opioid epidemic.”

About Relievant Medsystems

Relievant Medsystems is a privately-held medical device company that is transforming the treatment of Chronic Low Back Pain (CLBP) with the Intracept Procedure – a novel, clinically-proven and commercially-available treatment designed to improve the quality of life for the millions of patients suffering from CLBP from degenerative disk disease with Modic changes, a biomarker indicating that their pain is vertebrogenic in origin. Learn more at www.relievant.com.

Contact

Chris Geyen
Relievant Medsystems
(650) 368-1000
investors@relievant.com

Categories: News

Tags:

Nemera boosts parenteral product portfolio and small series capabilities in latest acquisition

Montagu

This acquisition strengthens Nemera’s proprietary product offering and establishes operations footprint in Eastern Europe.

Nemera today announced that they have entered into an agreement to acquire Copernicus. Copernicus, based in Szczecin Poland, specializes in the development and manufacturing of injection devices. Their range of reusable and disposable pen injectors are tailored for the treatment of several chronic pathologies.

We’re about to write a new chapter of Nemera’s growth story and I’m really excited about our bright future.

Marc Hämel, CEO of Nemera

Founded in 2004, Copernicus is regarded as one of the most valued innovative companies in the Polish health sector. They provide a comprehensive range of services in the introduction of modern and intuitive parenteral drug delivery devices.

This acquisition reinforces Nemera’s vision of becoming the most patient-centric drug device combination solutions company. It bolsters the company’s small series production capabilities, R&D expertise and parenteral product offering. Most importantly it expands their overall proprietary product portfolio. Copernicus’s fast and agile clinical manufacturing, adapted for small series, complements Nemera’s historical large-scale manufacturing capabilities. Furthermore, Copernicus’s marketed reusable pen injectors are of great value from a sustainability standpoint.

With this acquisition Nemera establishs an operations footprint in Eastern Europe. In order to accompany Copernicus’s solid forecasted growth, they will work together to build a new state-of-the-art manufacturing facility in Szczecin, Poland.

Marc Hämel, CEO of Nemera said, “This acquisition is a great strategic and cultural fit for us. Copernicus’ strong focus on patient needs aligns perfectly with our purpose of always putting the patient at the center of everything we do. We’re about to write a new chapter of Nemera’s growth story and I’m really excited about our bright future”.

“Nemera’s unaltered focus on patient needs and passion to develop combination product solutions of the future convinced us that this was the right next step. We’re thrilled to join Nemera and together make products that truly improve patients’ lives” added Alberto Lozano, CEO of Copernicus.

Montagu first partnered with Nemera in its 2014 carve-out from Rexam.  Montagu reinvested in the business in 2019 supporting its ambitious organic and acquisitive growth plans.

Categories: News

Tags:

Nemera boosts parenteral product portfolio and small series capabilities in latest acquisition

Montagu

his acquisition strengthens Nemera’s proprietary product offering and establishes operations footprint in Eastern Europe.

Nemera today announced that they have entered into an agreement to acquire Copernicus. Copernicus, based in Szczecin Poland, specializes in the development and manufacturing of injection devices. Their range of reusable and disposable pen injectors are tailored for the treatment of several chronic pathologies.

We’re about to write a new chapter of Nemera’s growth story and I’m really excited about our bright future.

Marc Hämel, CEO of Nemera

Founded in 2004, Copernicus is regarded as one of the most valued innovative companies in the Polish health sector. They provide a comprehensive range of services in the introduction of modern and intuitive parenteral drug delivery devices.

This acquisition reinforces Nemera’s vision of becoming the most patient-centric drug device combination solutions company. It bolsters the company’s small series production capabilities, R&D expertise and parenteral product offering. Most importantly it expands their overall proprietary product portfolio. Copernicus’s fast and agile clinical manufacturing, adapted for small series, complements Nemera’s historical large-scale manufacturing capabilities. Furthermore, Copernicus’s marketed reusable pen injectors are of great value from a sustainability standpoint.

With this acquisition Nemera establishs an operations footprint in Eastern Europe. In order to accompany Copernicus’s solid forecasted growth, they will work together to build a new state-of-the-art manufacturing facility in Szczecin, Poland.

Marc Hämel, CEO of Nemera said, “This acquisition is a great strategic and cultural fit for us. Copernicus’ strong focus on patient needs aligns perfectly with our purpose of always putting the patient at the center of everything we do. We’re about to write a new chapter of Nemera’s growth story and I’m really excited about our bright future”.

“Nemera’s unaltered focus on patient needs and passion to develop combination product solutions of the future convinced us that this was the right next step. We’re thrilled to join Nemera and together make products that truly improve patients’ lives” added Alberto Lozano, CEO of Copernicus.

Montagu first partnered with Nemera in its 2014 carve-out from Rexam.  Montagu reinvested in the business in 2019 supporting its ambitious organic and acquisitive growth plans.

Categories: News

Tags:

Oakley acquires WindStar Medical

Oakley

Oakley Capital (“Oakley”) is pleased to announce that it has agreed to acquire WindStar Medical GmbH (“WindStar Medical”) from ProSiebenSat.1 majority-owned NuCom Group.

WindStar Medical is Germany’s leading over-the-counter (“OTC”) consumer healthcare company. The platform, which is expected to generate over €120 million in revenues this year, designs, develops and commercialises branded consumer health and private label products, with a track record of establishing best-in-class medical formulations and brands.

The Consumer Brands segment of WindStar Medical offers a wide range of premium high-growth branded products in Germany, including SOS (wound care / disinfectants), Zirkulin (gastro-intestinal care), GreenDoc (mental wellbeing) and EyeMedica (eye health). WindStar Medical is also a provider of Private Label products to the leading German drug stores and supermarkets, whilst also developing an international distribution footprint through existing and new partners.

WindStar Medical benefits from the long-term structural growth of Germany’s consumer health market. This growth is being driven both by demographic trends, such as an ageing population, and a shift in consumer preferences driven by factors such as increased awareness of physical and mental wellbeing and willingness to prevent illness. Through its investment, Oakley will support the company’s management team as they continue to drive revenue growth, product innovation, digitalisation, as well as identifying opportunities to scale the business through accretive acquisitions.

The investment in WindStar Medical builds on Oakley’s successful track record of investing in leading consumer platforms in the DACH region, including Verivox, Parship Elite and more recently Wishcard Technologies and 7NXT / Gymondo. The business displays the typical Oakley deal characteristics, as it has an asset-light business model, industry-leading operational capabilities, and an attractive growth profile.

 

“WindStar Medical is a unique OTC platform in a highly attractive space that Oakley is excited to be investing in, having closely followed both the development of the business and management over recent years. We look forward to working together with the team and utilising our broad expertise in digitalisation, go-to-market and M&A to help WindStar Medical accelerate its growth trajectory in Germany and international markets.”
Peter Dubens
Managing Partner of Oakley Capital

Categories: News

Tags:

Avedon expands DELABO.GROUP with acquisitions of Rauschelbach Zahntechnik, Dentaltechnik Knebelsberger and Laufer Zahntechnik

Avedon

Düsseldorf, October 21st, 2020 – DELABO.GROUP, a leading German platform of dental laboratories backed by Avedon Capital Partners, is glad to announce the acquisitions of Rauschelbach Zahntechnik GmbH, Dentaltechnik Knebelsberger GmbH and Laufer Zahntechnik GmbH. The addition of these three independent German dental laboratories with complementary technical and operational capabilities will strengthen the group and firmly establish DELABO.GROUP among the 5 largest players in the German dental laboratory market.

DELABO.GROUP was founded in September 2019 and pursues a buy & build strategy in the fragmented German dental laboratories market. Since foundation, the group already conducted 7 transactions and will likely double in size by the end of 2020 as compared to the initial platform. The group offers a comprehensive portfolio of domestically produced dental prosthetics across all relevant price/quality combinations as well as a wide range of high-end services. Today, the combined group employs more than 230 employees across 8 locations. Investments into technology and the harmonization of production processes, a shared organizational set-up as well as in strategic sales and marketing initiatives are ongoing and are slowly starting to bear fruit.

Thomas Dold, CEO DELABO.GROUP:
“We are very pleased to welcome these three excellent labs to the DELABO.GROUP and thereby further expand our network and our presence in both North- and South-Germany. These acquisitions perfectly fit with our strategy and it will be the beginning of a fruitful partnership. It is great to see that we are able to enthuse such exceptional entrepreneurs like Frank Rauschelbach, Ralf Schieweg and Andreas Laufer with our concept and together, we will accelerate the impressive growth the DELABO.GROUP has achieved thus far. Especially in these uncertain times, this is a strong sign that we are on the right track with our value proposition and our vision.”

About Rauschelbach Zahntechnik GmbH
Rauschelbach Zahntechnik in Pinneberg near Hamburg is an innovative dental laboratory characterized by outstanding expertise in the field of implantology, combination technology and anterior aesthetics. Managing Director Frank Rauschelbach focuses on digitalization in combination with individual craftsmanship as well as a personal exchange with dentists and patients. With this renowned partner laboratory, the DELABO.GROUP strengthens its position in the market and further expands its presence in northern Germany.

About Dentaltechnik Knebelsberger GmbH
Dentaltechnik Knebelsberger is located in Karlsruhe and is headed by Managing Director Ralf Schieweg, who has been working for the company since 1993. With more than 40 employees, Knebelsberger Zahntechnik covers the entire spectrum of modern, digital dental technology. Special expertise includes innovative measuring systems and computer-aided CAD/CAM systems as well as the treatment of functional disorders with the DIR system. The claim of Knebelsberger Zahntechnik is: Quality in all technical and aesthetic aspects as well as strong service and reliability.

About Laufer Zahntechnik GmbH
Laufer Zahntechnik GmbH is located in Mannheim and operates nation-wide and is one of the largest and leading dental laboratories in Germany in the field of implantology and combined dentures. Laufer Zahntechnik was founded in 1989 by master dental technician Andreas Laufer, who is the managing director of the laboratory, now employing around 50 employees. The innovative entrepreneur has always invested in new technologies, which is why Laufer Zahntechnik was, for example, one of the first laboratories in Germany with a high-precision 3D metal printer.

About the DELABO.GROUP
DELABO.GROUP is a buy & build platform in the fragmented German dental laboratories market. The value proposition of the group is based on its comprehensive product offering, which comprises all medically relevant price-quality product combinations as well as a broad range of supportive services for dentists and patients. Despite acting as a nation-wide dental lab platform, the Group emphasizes the regional character of the dental laboratories by leveraging the respective brand heritage as well as the local presence of each group lab. DELABO.GROUP labs are supported in terms of administrative activities, operational investments, recruitment of skilled labor force and the exploration of different growth avenues. Additionally, the Group seeks to extend its geographical coverage as well as its regional presence by pursuing further acquisitions of dental labs in the upcoming years. For more information please visit https://www.delabo.com.

About Avedon Capital Partners
Avedon is a leading growth capital investor based in Amsterdam and Düsseldorf. Avedon invests in small and medium-sized companies in Western Europe with a focus on the software & technology, industrials, consumer & leisure, and business services sectors. Avedon works closely with its management teams to realize growth ambitions and has a long track record of successfully delivering results through autonomous growth and buy-and-build strategies. For more information please visit www.avedoncapital.com.

Categories: News

Tags: